J Hematol Oncol
The Journal of Hematology & Oncology is a premier, peer-reviewed, open-access publication dedicated to advancing the understanding and treatment of hematologic malignancies and related oncologic disorders. With an impressive 2026 Impact Factor of 23.1680 and a JCR Quartile ranking of Q1, the journal stands among the most influential and highly cited periodicals in its field. Published by BioMed Central, part of Springer Nature, the journal ensures immediate, worldwide access to its content under a Creative Commons license, facilitating rapid dissemination of critical findings to the global scientific community. The journal’s scope encompasses a broad spectrum of topics, including leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and solid tumors, with a strong focus on molecular biology, immunology, targeted therapies, immunotherapy, and stem cell transplantation. It welcomes original research articles, comprehensive reviews, clinical trials, and case reports that provide novel insights into disease mechanisms, diagnostics, and treatment strategies. The journal particularly values translational studies that bridge laboratory discoveries with clinical applications. The target audience includes hematologists, oncologists, clinical researchers, translational scientists, and medical professionals seeking cutting-edge developments in cancer biology and therapeutics. Notable features include a rigorous, single-blind peer-review process, a dedicated editorial board of international experts, and high visibility through indexing in major databases such as PubMed, Scopus, and Web of Science. By consistently publishing groundbreaking work and maintaining exceptional citation metrics, the Journal of Hematology & Oncology has solidified its status as a leading venue for high-impact research driving progress in hematology and oncology.